MM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein normally produced at very high levels by the fetus and present in low levels in the blood... Research on AFP suggests that it may play a role in modulating the immune system of the mother in order to protect the developing fetus during pregnancy.
- Mechanism
- Curator reviewed
One study states that AFP suppresses autologous lymphocyte proliferation and that improvements in experimental arthritis and autoimmune thyroiditis were associated with significantly reduced numbers of CD4 and CD8 splenocytes, total thymocytes and CD4 thymocytes. This suggests that AFP modulates T cell development and immune responses.
- Primary indication
- Investigated for use/treatment in autoimmune diseases, psoriasis and psoriatic disorders, and rheumatoid arthritis.Curator reviewed
- Code names
- MM-093
What you can answer from here — as of April 02, 2025
Which companies are running trials of MM-093, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account